NVAX: Novavax Pharma Cash Funds per Share

Symbol and logo of brand Novavax Pharma (NVAX)

A streamlined network of global carriers ensured uninterrupted deliveries, triggering a sharp rally on the chart. The cash per share metric confirms financial stability, while 3.80 determines the latest valuation figure. Novavax, Inc. (NVAX) maintains market confidence through its reputation as a creator of safe protein-based drugs, although its profitability depends on government contracts and seasonal spikes in disease incidence, creating volatility in results.

Novavax Pharma (NVAX): Cash per Single Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for Novavax Inc (NVAX)

- price and consensus price forecast:
- market capitalization information:
- cash and cash flow data:
Comprehensive company analysis:Novavax Corp NVAX
Flagship merchandise of Novavax

This indicator reflects the volume of liquid assets per common share by dividing the total cash balance by the number of outstanding securities. An analysis of cash per share allows for an assessment of the ability of Novavax, Inc. (NVAX) to fund costly R&D projects and retain highly qualified virologists, ensuring the stability of research-intensive recombinant vaccine development without resorting to external borrowing.